Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 477 Jan 1 – Oct 25, 2026
- Disclosed funding
- $20.2B 403 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| IL Isomorphic LabsCompany profile Builds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas Builds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas | $2.1B | Series B | Biotech | United Kingdom | Investors | |
 AlgorithmiqCompany profile Algorithmiq develops quantum algorithms and software for research in chemistry, materials and life sciences. Algorithmiq develops quantum algorithms and software for research in chemistry, materials and life sciences. | €18M | Series B | Biotech, Developer tools | Italy | Investors | |
| N Develops nanostructured sensor chips for rapid pathogen detection in food | €2.6M | Seed | Biotech | Germany | Investors | |
| P ParcelBioCompany profile Develops potent and durable mRNA medicines using the APEXm platform for autoimmune and oncology Develops potent and durable mRNA medicines using the APEXm platform for autoimmune and oncology | $13M | Seed | Biotech | United States | Investors | |
| M Develops cultivated meat production technology | £10.4M | Series A | Biotech, Foodtech | United Kingdom | Investors | |
| C CellCentricCompany profile Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma | $220M | Series DSeries C+ | Biotech | United Kingdom | Investors | |
| KB Kanvas BiosciencesCompany profile Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy | $48M | Series A | Biotech | United States | Investors | |
| LT LTZ TherapeuticsCompany profile LTZ Therapeutics develops cancer immunotherapies that target myeloid biology. LTZ Therapeutics develops cancer immunotherapies that target myeloid biology. | $38M | Undisclosed | Biotech | United States | Investors | |
| SB Signadori BioCompany profile Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage | €11.1M | Seed+Seed | Biotech | France | Investors | |
| PH Pacific HybreedCompany profile Develops high-performance hybrid oyster and clam seed to improve yield and resilience for shellfish farmers Develops high-performance hybrid oyster and clam seed to improve yield and resilience for shellfish farmers | $1M | Seed | Biotech, Agritech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
23rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.